SURVYR

ABT

Abbott Laboratories
$102.67
−$0.43 (0.42%)Oct 28 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-34%-22%-10%+3%+15%Oct 2025Oct 2026Apr 202652w high $132.0352w low $81.97
ABTSPY
Wall St. Highest PT $130.00 (+26.6%) Wall St. Avg PT $118.64 (+15.6%)
$81$99$117$134$152POC $122Hi $130Avg $119
Underwater Drawdown %Max DD -36.1%Current -19.4%
0.0%-36.1%
Relative Strength vs SPY-31.2% vs SPYUnderperforming
+49%0%-49%
1W
+$2.16 (2.15%)
1M
+$2.31 (2.30%)
3M
−$4.67 (4.35%)
6M
+$12.54 (13.92%)
YTD
−$19.58 (16.02%)
1Y
−$20.87 (16.89%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
26 analysts · mean score 1.46
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$102.67
Average target$118.64
+$15.97 (+15.6%) upsideaverage target vs current price
CurrentAverageMedian
Low$103.00
Median$118.64
High$130.00
12-month Wall Street target range

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$179.4B
P/E (last 12 months)38.6
P/E (next 12 months, estimated)17.4
52-week range$81.97 – $132.03
Revenue growth (latest quarter vs a year ago)+14.5%
Dividend yield2.43%
Analyst consensusStrong Buy (26)
Average analyst price target$118.64 (+16%)

What they do

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm.

Healthcare · Medical Devices
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
17th percentile in sector
D
12-1 return: -18.6%
Percentile within its GICS sector across the S&P 1500.
Growth
68th percentile in sector
B
Revenue growth (YoY): +13.0%
Percentile within its GICS sector across the S&P 1500.
Value
46th percentile in sector
C
Forward E/P: 5.8% · EBITDA/EV: 5.6%
Percentile within its GICS sector across the S&P 1500.
Profitability
57th percentile in sector
B-
Profit margin: +11.6% · Return on equity: +10.6%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 424 of 499 · 12-month momentum -15.7%
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

ABT earningsReported Oct 21, 2026● In line with estimates
Results · Before the open
EPS actual$1.42
EPS estimate$1.42
Surprise+0.0%
RevenueNot in our data yet

Revenue for this quarter is not in our data yet. It arrives with the quarterly filing.

Next report
Thu Jan 28, 2027Before the open
EPS consensus$1.64
Revenue consensus–
Last 4 quarters · EPS vs estimate
Oct 21, 2026$1.42est $1.42+0.0%In line with estimates
Jul 16, 2026$1.31est $1.28+2.6%Above estimates
Apr 16, 2026$1.15est $1.15+0.3%In line with estimates
Jan 22, 2026$1.50est $1.49+0.3%In line with estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-26 18:40:20 ET
25-0125-0425-0725-1026-0126-0426-0726-100.001.50
EstimateActual (beat)Actual (miss)

News & catalysts

More news
Apple Stock And Other Quality Growth Names For Higher Rates
Simply Wall St. · 4h ago
What Would A Short Seller Say About Stryker?
Trefis · 16h ago
Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy?
Nasdaq · Oct 24
Can Boston Scientific Stock Bounce Off This Support Again?
Trefis · Oct 21
Abbott to Spin Off Troubled Nutrition Unit to Focus on Growth
Barrons.com · Oct 21
Insider trades
Mccoy John A. Jr.
VICE PRESIDENT AND CONTROLLER · 2026-09-02
Sell
$3.0K
Ford Robert B
Director, CHAIRMAN AND CEO · 2026-08-25
Sell
$20.9M
Ford Robert B
Director, CHAIRMAN AND CEO · 2026-08-25
Sell
$25.3M
Morrone Louis H.
EXECUTIVE VICE PRESIDENT · 2026-08-11
Sell
$642.5K
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-26 18:40:20 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026